Colman Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Colman Taylor has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- John Myburgh
Critical Care Program, The George Institute for Global Health, UNSW Sydney, Australia
8 shared publications - Stephen Jan
The George Institute for Global Health, UNSW, Sydney, Australia
7 shared publications - Naomi E. Hammond
The George Institute for Global Health, University of New South Wales, Sydney, Australia
5 shared publications - Jacqui Webster
University of Technology Sydney
4 shared publications Adrian Peacock
Health Technology Analysts Pty Ltd, Surry Hills, Australia
3 shared publicationsDo Thi Phuong Ha
National Institute of Nutrition, Hanoi, Viet Nam
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 783-794
Rural-urban disparities in the clinical diagnostic pathway of patients with all-cause mild cognitive impairment and dementia due to Alzheimer's disease in Australia
Background: Access to high-quality and timely dementia diagnoses varies between rural and urban location. Objective: We examined rural-urban disparities in key indicators for high-quality and timely diagnoses of mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia in Australia. Methods: 3648 patients with all-cause MCI or AD dementia were geographically classified into major cities (75.7%), inner (15.8%) and outer (8.4%) regional areas. We used regression analyses to assess rural-urban disparities in completion of key diagnostic investigations and diagnostic wait times. Results: Participants in inner regional areas were more likely (odds ratio [OR] = 1.55; 95% confidence interval [CI] = 1.14, 2.13; p = 0.006) to have had more basic diagnostic investigations completed (including core blood tests, cognitive assessments, functional assessments, structural neuroimaging) compared to those in major cities. However, participants in inner regional (OR = 0.37; 95% CI = 0.28, 0.48; p < 0.001) and outer regional (OR = 0.32; 95% CI = 0.21, 0.48; p < 0.001) areas were less likely to have functional neuroimaging completed. Median wait times for an initial appointment following referral to a memory clinic were up to 28 days longer for rural compared to urban participants (Inner regional: Beta (median) = 12.91; 95% CI = 5.15, 20.69; p = 0.001; Outer regional: Beta (median) = 27.50; 95% CI = 18.80, 36.20; p < 0.001), whereas median wait times from initial appointment to diagnosis were up to 47 days shorter in rural compared to urban residents (Inner regional: Beta (median) = −46.83; 95% CI = −52.35, −41.32; p < 0.001; Outer regional: Beta (median) = −44.42; 95% CI = −50.35, −38.49; p < 0.001). Conclusions: Findings suggest disparities in access to advanced diagnostic investigations and timely initial appointments in rural Australia, and increased need for enhanced workforce and diagnostic infrastructure in these areas.
- 29 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 783-794
Open AccessRural-urban disparities in the clinical diagnostic pathway of patients with all-cause mild cognitive impairment and dementia due to Alzheimer's disease in Australia
Background: Access to high-quality and timely dementia diagnoses varies between rural and urban location. Objective: We examined rural-urban disparities in key indicators for high-quality and timely diagnoses of mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia in Australia. Methods: 3648 patients with all-cause MCI or AD dementia were geographically classified into major cities (75.7%), inner (15.8%) and outer (8.4%) regional areas. We used regression analyses to assess rural-urban disparities in completion of key diagnostic investigations and diagnostic wait times. Results: Participants in inner regional areas were more likely (odds ratio [OR] = 1.55; 95% confidence interval [CI] = 1.14, 2.13; p = 0.006) to have had more basic diagnostic investigations completed (including core blood tests, cognitive assessments, functional assessments, structural neuroimaging) compared to those in major cities. However, participants in inner regional (OR = 0.37; 95% CI = 0.28, 0.48; p < 0.001) and outer regional (OR = 0.32; 95% CI = 0.21, 0.48; p < 0.001) areas were less likely to have functional neuroimaging completed. Median wait times for an initial appointment following referral to a memory clinic were up to 28 days longer for rural compared to urban participants (Inner regional: Beta (median) = 12.91; 95% CI = 5.15, 20.69; p = 0.001; Outer regional: Beta (median) = 27.50; 95% CI = 18.80, 36.20; p < 0.001), whereas median wait times from initial appointment to diagnosis were up to 47 days shorter in rural compared to urban residents (Inner regional: Beta (median) = −46.83; 95% CI = −52.35, −41.32; p < 0.001; Outer regional: Beta (median) = −44.42; 95% CI = −50.35, −38.49; p < 0.001). Conclusions: Findings suggest disparities in access to advanced diagnostic investigations and timely initial appointments in rural Australia, and increased need for enhanced workforce and diagnostic infrastructure in these areas.
- Open Access
- 4 April 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (5) , 743-750
Evaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context
Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy of these predictions for the cancer drug pembrolizumab, using models preferred by pharmaceutical companies (Sponsors) and the Pharmaceutical Benefits Advisory Committee (PBAC), compared to real-world long-term follow-up (LTFU) data. We reviewed publicly available PBAC summary documents (PSDs) for all funding decisions on pembrolizumab up to November 2022. We included cases with at least three years of follow-up data and where at least 350 patients per year would be treated. We then compared survival predictions from PBAC and Sponsor models to actual survival data at two time points. A total over 38 PSDs covering 15 indications, five met our criteria. Sponsor-preferred models underestimated real survival by 0.54% to 16.45%, while PBAC-preferred models underestimated survival by 1.20% to 24.21%. Results demonstrate that OS extrapolation methods used by both the Sponsor and PBAC tend to underestimate long-term survival outcomes for pembrolizumab indications, with PBAC-preferred methods being more conservative.
- 4 April 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (5) , 743-750
Open AccessEvaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context
Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy of these predictions for the cancer drug pembrolizumab, using models preferred by pharmaceutical companies (Sponsors) and the Pharmaceutical Benefits Advisory Committee (PBAC), compared to real-world long-term follow-up (LTFU) data. We reviewed publicly available PBAC summary documents (PSDs) for all funding decisions on pembrolizumab up to November 2022. We included cases with at least three years of follow-up data and where at least 350 patients per year would be treated. We then compared survival predictions from PBAC and Sponsor models to actual survival data at two time points. A total over 38 PSDs covering 15 indications, five met our criteria. Sponsor-preferred models underestimated real survival by 0.54% to 16.45%, while PBAC-preferred models underestimated survival by 1.20% to 24.21%. Results demonstrate that OS extrapolation methods used by both the Sponsor and PBAC tend to underestimate long-term survival outcomes for pembrolizumab indications, with PBAC-preferred methods being more conservative.
- Open Access
- 10 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12937
Advancing Health Research Impact through a Systemic Multi-Sectoral Approach: A Protocol for Introducing Reduced-Sodium Salts and Salty Condiments in Vietnam
Better alignment between health research organisations with the needs (and interests) of key stakeholders in the health policy and research system is critical to improving research impact. The George Institute for Global Health’s ‘Healthier Societies’ program focuses on harnessing the power of governments, markets, and communities to improve population level health equity outcomes and maximise research impact. This protocol outlines a systemic multi-sectoral approach to advance health research impact globally applied to a project to reduce population salt intake in Vietnam by introducing reduced-sodium salts and salty condiments. We defined a systemic multi-sectoral approach to be a strategy that involves engaging with government, market and communities in a deliberate and joined-up way to solve a problem in which they all have a role to play. The project objectives are to: (i) produce reduced-sodium fish sauce products and test consumer acceptability; (ii) investigate the market feasibility of introducing reduced-sodium foods (salt, bot canh and fish sauce) into the Vietnamese market; (iii) estimate the cost-effectiveness of three different government strategies to support the implementation of reduced-sodium products; and (iv) develop an advocacy roadmap to maximise potential research impact. Methods will include standard quality and safety assessments, consumer sensory testing for the locally produced reduced-sodium fish sauces, market feasibility assessment (including collating market data and semi-structured interviews with stakeholders), cost-effectiveness modelling (Markov cohort model), multi-sector stakeholder engagement, and the development of a coordinated advocacy strategy using the Kotter Plus framework. Health research organisations are increasingly seeking ways to achieve greater impact with their research. Through the application of a systemic multi-sectoral approach with governments, markets and communities, this protocol provides an example of how health research projects can achieve such impact.
- 10 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12937
Open AccessAdvancing Health Research Impact through a Systemic Multi-Sectoral Approach: A Protocol for Introducing Reduced-Sodium Salts and Salty Condiments in Vietnam
Better alignment between health research organisations with the needs (and interests) of key stakeholders in the health policy and research system is critical to improving research impact. The George Institute for Global Health’s ‘Healthier Societies’ program focuses on harnessing the power of governments, markets, and communities to improve population level health equity outcomes and maximise research impact. This protocol outlines a systemic multi-sectoral approach to advance health research impact globally applied to a project to reduce population salt intake in Vietnam by introducing reduced-sodium salts and salty condiments. We defined a systemic multi-sectoral approach to be a strategy that involves engaging with government, market and communities in a deliberate and joined-up way to solve a problem in which they all have a role to play. The project objectives are to: (i) produce reduced-sodium fish sauce products and test consumer acceptability; (ii) investigate the market feasibility of introducing reduced-sodium foods (salt, bot canh and fish sauce) into the Vietnamese market; (iii) estimate the cost-effectiveness of three different government strategies to support the implementation of reduced-sodium products; and (iv) develop an advocacy roadmap to maximise potential research impact. Methods will include standard quality and safety assessments, consumer sensory testing for the locally produced reduced-sodium fish sauces, market feasibility assessment (including collating market data and semi-structured interviews with stakeholders), cost-effectiveness modelling (Markov cohort model), multi-sector stakeholder engagement, and the development of a coordinated advocacy strategy using the Kotter Plus framework. Health research organisations are increasingly seeking ways to achieve greater impact with their research. Through the application of a systemic multi-sectoral approach with governments, markets and communities, this protocol provides an example of how health research projects can achieve such impact.
- 1 May 2022
- Published by Elsevier in Australian Critical Care
- Vol. 35 (3) , 241-250
Long-term costs and cost-effectiveness of adjunctive corticosteroids for patients with septic shock in New Zealand
- 1 May 2022
- Published by Elsevier in Australian Critical Care
- Vol. 35 (3) , 241-250
Long-term costs and cost-effectiveness of adjunctive corticosteroids for patients with septic shock in New Zealand
- 25 March 2022
- Published by Elsevier in Australian Critical Care
- Vol. 36 (3) , 431-437
Economic evaluations for intensive care unit randomised clinical trials in Australia and New Zealand: Practical recommendations for researchers
- 25 March 2022
- Published by Elsevier in Australian Critical Care
- Vol. 36 (3) , 431-437
Economic evaluations for intensive care unit randomised clinical trials in Australia and New Zealand: Practical recommendations for researchers
- Open Access
- 6 September 2021
- Published by College Of Intensive Care Medicine Of Australia And New Zealand in Critical Care and Resuscitation
- Vol. 23 (3) , 273-284
Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis.
- 6 September 2021
- Published by College Of Intensive Care Medicine Of Australia And New Zealand in Critical Care and Resuscitation
- Vol. 23 (3) , 273-284
Open AccessStatistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis.
- 1 September 2021
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 121 (9) , A57
Millennials Self-Reported Diet Quality is Associated with Adherence to MyPlate Recommendations, Consumer Behavior, Food Security, and Mental Health
- 1 September 2021
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 121 (9) , A57
Millennials Self-Reported Diet Quality is Associated with Adherence to MyPlate Recommendations, Consumer Behavior, Food Security, and Mental Health
- Open Access
- 11 March 2021
- Published by Springer Nature in Archives of Public Health
- Vol. 79 (1) , 1-13
The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam
Background: Dietary sodium reduction is recommended to reduce the burden of cardiovascular disease. In Vietnam food products including salt, fish sauce and bot canh contribute to ~ 70% of dietary sodium intake. Reduced sodium versions of these products can be produced by replacing some of the sodium chloride with potassium chloride. We aimed to assess the cost-effectiveness of three alternative approaches to introducing reduced sodium products onto the market with a view to lowering population sodium intake in Vietnam. Methods: The three salt substitution strategies included voluntary, subsidised and regulatory approaches targeting salt, fish sauce and bot canh products. Costs were modelled using the WHO-CHOICE methodology. A Markov cohort model was developed to evaluate the cost-effectiveness of each strategy versus no intervention from the government perspective. The model linked each intervention strategy to assumed changes in levels of sodium intake and then to systolic blood pressure. Changes in SBP were linked to a probability of ischaemic heart disease or stroke. The model followed people over their lifetime to assess average costs and quality adjusted life years (QALYs) gained for each strategy. Results: The voluntary salt substitution strategy was assumed to require no investment by government. Following ramp up (years 6+), the average annual costs for the subsidised and regulatory strategies were 21,808,968,902 ₫ (US$ 977,354) and 12,949,953,247 ₫ (US$ 580,410) respectively. Relative to no intervention, all three salt substitution strategies were found to be cost-effective. Cost savings were driven by reductions in strokes (32,595; 768,384; 2,366,480) and ischaemic heart disease (IHD) events (22,830; 537,157; 1,648,590) for the voluntary, subsidised & regulatory strategies, respectively. The voluntary strategy was least cost-effective (− 3445 ₫ US$ -0.15; 0.009 QALYs gained) followed by the subsidised strategy (− 43,189 ₫ US$ -1.86; 0.022 QALYs gained) and the regulatory strategy delivered the highest cost savings and health gains (− 243,530 ₫ US$ -10.49; 0.074 QALYs gained). Conclusion: This research shows that all three modelled salt substitution strategies would be good value for money relative to no intervention in Vietnam. The subsidised alternative would require the highest level of government investment; however the implementation costs will be exceeded by healthcare savings assuming a reasonable time horizon is considered.
- 11 March 2021
- Published by Springer Nature in Archives of Public Health
- Vol. 79 (1) , 1-13
Open AccessThe cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam
Background: Dietary sodium reduction is recommended to reduce the burden of cardiovascular disease. In Vietnam food products including salt, fish sauce and bot canh contribute to ~ 70% of dietary sodium intake. Reduced sodium versions of these products can be produced by replacing some of the sodium chloride with potassium chloride. We aimed to assess the cost-effectiveness of three alternative approaches to introducing reduced sodium products onto the market with a view to lowering population sodium intake in Vietnam. Methods: The three salt substitution strategies included voluntary, subsidised and regulatory approaches targeting salt, fish sauce and bot canh products. Costs were modelled using the WHO-CHOICE methodology. A Markov cohort model was developed to evaluate the cost-effectiveness of each strategy versus no intervention from the government perspective. The model linked each intervention strategy to assumed changes in levels of sodium intake and then to systolic blood pressure. Changes in SBP were linked to a probability of ischaemic heart disease or stroke. The model followed people over their lifetime to assess average costs and quality adjusted life years (QALYs) gained for each strategy. Results: The voluntary salt substitution strategy was assumed to require no investment by government. Following ramp up (years 6+), the average annual costs for the subsidised and regulatory strategies were 21,808,968,902 ₫ (US$ 977,354) and 12,949,953,247 ₫ (US$ 580,410) respectively. Relative to no intervention, all three salt substitution strategies were found to be cost-effective. Cost savings were driven by reductions in strokes (32,595; 768,384; 2,366,480) and ischaemic heart disease (IHD) events (22,830; 537,157; 1,648,590) for the voluntary, subsidised & regulatory strategies, respectively. The voluntary strategy was least cost-effective (− 3445 ₫ US$ -0.15; 0.009 QALYs gained) followed by the subsidised strategy (− 43,189 ₫ US$ -1.86; 0.022 QALYs gained) and the regulatory strategy delivered the highest cost savings and health gains (− 243,530 ₫ US$ -10.49; 0.074 QALYs gained). Conclusion: This research shows that all three modelled salt substitution strategies would be good value for money relative to no intervention in Vietnam. The subsidised alternative would require the highest level of government investment; however the implementation costs will be exceeded by healthcare savings assuming a reasonable time horizon is considered.
- Open Access
- 12 February 2021
- Published by Springer Nature in Research Square
The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam
Background Dietary sodium reduction is recommended to reduce the burden of cardiovascular disease. In Vietnam food products including salt, fish sauce and bot canh contribute to ~70% of dietary sodium intake. Reduced sodium versions of these products can be produced by replacing some of the sodium chloride with potassium chloride. We aimed to assess the cost-effectiveness of three alternative approaches to introducing reduced sodium products onto the market with a view to lowering population sodium intake in Vietnam.Methods The three salt substitution strategies included voluntary, subsidised and regulatory approaches targeting salt, fish sauce and bot canh products. Costs were modelled using the WHO-CHOICE methodology. A Markov cohort model was developed to evaluate the cost-effectiveness of each strategy versus no intervention from the government perspective. The model linked each intervention strategy to assumed changes in levels of sodium intake and then to systolic blood pressure. Changes in SBP were linked to a probability of ischaemic heart disease or stroke. The model followed people over their lifetime to assess average costs and quality adjusted life years (QALYs) gained for each strategy. Results The voluntary salt substitution strategy was assumed to require no investment by government. Following ramp up (years 6+), the average annual costs for the subsidised and regulatory strategies were 21,808,968,902 ₫ (US$ 977,354) and 12,949,953,247 ₫ (US$ 580,410) respectively. Relative to no intervention, all three salt substitution strategies were found to be cost-effective. Cost savings were driven by reductions in strokes (32,595; 768,384; 2,366,480) and ischaemic heart disease (IHD) events (22,830; 537,157; 1,648,590) for the voluntary, subsidised & regulatory strategies, respectively. The voluntary strategy was least cost-effective (-3,445 ₫ US$ -0.15; 0.009 QALYs gained) followed by the subsidised strategy (-43,189 ₫ US$ -1.86; 0.022 QALYs gained) and the regulatory strategy delivered the highest cost savings and health gains (-243,530 ₫ US$ -10.49; 0.074 QALYs gained). Conclusion This research shows that all three modelled salt substitution strategies would be good value for money relative to no intervention in Vietnam. The subsidised alternative would require the highest level of government investment; however the implementation costs will be exceeded by healthcare savings assuming a reasonable time horizon is considered.
- 12 February 2021
- Published by Springer Nature in Research Square
Open AccessThe cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam
Background Dietary sodium reduction is recommended to reduce the burden of cardiovascular disease. In Vietnam food products including salt, fish sauce and bot canh contribute to ~70% of dietary sodium intake. Reduced sodium versions of these products can be produced by replacing some of the sodium chloride with potassium chloride. We aimed to assess the cost-effectiveness of three alternative approaches to introducing reduced sodium products onto the market with a view to lowering population sodium intake in Vietnam.Methods The three salt substitution strategies included voluntary, subsidised and regulatory approaches targeting salt, fish sauce and bot canh products. Costs were modelled using the WHO-CHOICE methodology. A Markov cohort model was developed to evaluate the cost-effectiveness of each strategy versus no intervention from the government perspective. The model linked each intervention strategy to assumed changes in levels of sodium intake and then to systolic blood pressure. Changes in SBP were linked to a probability of ischaemic heart disease or stroke. The model followed people over their lifetime to assess average costs and quality adjusted life years (QALYs) gained for each strategy. Results The voluntary salt substitution strategy was assumed to require no investment by government. Following ramp up (years 6+), the average annual costs for the subsidised and regulatory strategies were 21,808,968,902 ₫ (US$ 977,354) and 12,949,953,247 ₫ (US$ 580,410) respectively. Relative to no intervention, all three salt substitution strategies were found to be cost-effective. Cost savings were driven by reductions in strokes (32,595; 768,384; 2,366,480) and ischaemic heart disease (IHD) events (22,830; 537,157; 1,648,590) for the voluntary, subsidised & regulatory strategies, respectively. The voluntary strategy was least cost-effective (-3,445 ₫ US$ -0.15; 0.009 QALYs gained) followed by the subsidised strategy (-43,189 ₫ US$ -1.86; 0.022 QALYs gained) and the regulatory strategy delivered the highest cost savings and health gains (-243,530 ₫ US$ -10.49; 0.074 QALYs gained). Conclusion This research shows that all three modelled salt substitution strategies would be good value for money relative to no intervention in Vietnam. The subsidised alternative would require the highest level of government investment; however the implementation costs will be exceeded by healthcare savings assuming a reasonable time horizon is considered.
- 1 January 2021
- Published by Elsevier in Australian Critical Care
- Vol. 34 (1) , 23-32
An international comparison of the cost of fluid resuscitation therapies
- 1 January 2021
- Published by Elsevier in Australian Critical Care
- Vol. 34 (1) , 23-32
An international comparison of the cost of fluid resuscitation therapies